Shares of Mineralys Therapeutics Inc. (MLYS) are up nearly 40% at $21 in premarket trading, following AstraZeneca's (AZN) positive trial results for Baxdrostat, a highly selective aldosterone synthase inhibitor, or ASI, for hypertension. As Mineralys is also developing ASIs targeting hypertension and related cardiorenal conditions, the news has triggered a domino effect, lifting sentiment across the ASI space.
Mineralys' lead drug candidate is Lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension (uHTN) & resistant hypertension (rHTN), chronic kidney disease, and obstructive sleep apnea.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com